SUTRO BIOPHARMA INC

For the period ended Jun 30, 2024. Filed Aug 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 13, 2024

STRO$10.17-4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Stockholders’ Equity

(In thousands, except share amounts)

Accumulated
Additional · Other · Total
Common Stock · Paid-In- · Comprehensive · Accumulated · Stockholders’
Shares · Amount · Capital · Income (Loss) · Deficit · Equity
Balances at December 31, 2023	61,009,829	$61	$708,975	$21	$(559,408)		$149,649
Exercise of common stock options	23,748	—	117	—	—		117
Issuance of common stock under Employee Stock Purchase Plan	284,362	—	911	—	—		911
Vesting of restricted stock units	1,215,729	1	(1)	—	—		—
Stock transaction associated with taxes withheld on restricted stock units	(77,122)	—	(374)	—	—		(374)
Stock-based compensation expense	—	—	6,068	—	—		6,068
Net unrealized loss on available-for-sale securities	—	—	—	(134)	—		(134)
Net loss	—	—	—	—	(58,213)		(58,213)
Balances at March 31, 2024	62,456,546	$62	$715,696	$(113)	$(617,621)		$98,024
Vesting of restricted stock units	107,375	—	—	—	—		—
Stock transaction associated with taxes withheld on restricted stock units	(8,474)	—	(37)	—	—		(37)
Stock-based compensation expense	—	—	6,159	—	—		6,159
Issuance of common stock in connection with the underwritten offering, net of issuance costs of $3,474	14,478,764	15	71,512	—	—		71,527
Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement	4,827,373	5	24,566			24,571
Net unrealized loss on available-for-sale securities	—	—	—	(50)	—		(50)
Net loss	—	—	—	—	(48,018)		(48,018)
Balances at June 30, 2024	81,861,584	$82	$817,896	$(163)	$(665,639)		$152,176

	Accumulated
Additional · Other · Total
Common Stock · Paid-In- · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balances at December 31, 2022	57,499,541	$58	$670,223	$(618)	$(452,615)	$217,048
Exercise of common stock options	53,060	—	314	—	—	314
Issuance of common stock under Employee Stock Purchase Plan	239,060	—	1,097	—	—	1,097
Vesting of restricted stock units	801,769	—	—	—	—	—
Stock transaction associated with taxes withheld on restricted stock units	(73,003)	—	(451)	—	—	(451)
Stock-based compensation expense	—	—	6,021	—	—	6,021
Issuance of common stock in connection with At-The-Market sale, net of issuance costs of $308	1,641,374	2	10,921	—	—	10,923
Net unrealized income on available-for-sale securities	—	—	—	511	—	511
Net loss	—	—	—	—	(50,050)	(50,050)
Balances at March 31, 2023	60,161,801	$60	$688,125	$(107)	$(502,665)	$185,413
Vesting of restricted stock units	94,500	—	—	—	—	—
Stock transaction associated with taxes withheld on restricted stock units	(1,296)	—	(6)	—	—	(6)
Stock-based compensation expense	—	—	6,661	—	—	6,661
Issuance of common stock in connection with At-The-Market sale, net of issuance costs of $151	216,036	—	1,048	—	—	1,048
Net unrealized income on available-for-sale securities	—	—	—	123	—	123
Net loss	—	—	—	—	(38,524)	(38,524)
Balances at June 30, 2023	60,471,041	$60	$695,828	$16	$(541,189)	$154,715

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.